Editas Medicine
AWARDS
NEWS
Shares of Cambridge, Mass.-based Editas Medicine are down nearly 20 percent after Chief Executive Officer Katrine Bosley abruptly announced her decision to resign from her role at the company effective March 1.
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
It may not have always felt like it, but biotech has been in a bull market mode over the past two-and-a-half years, ever since the iShares Biotechnology Index (IBB) bottomed out at $80.01 on February 9, 2016.
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
It was a win for the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University, as a federal court of appeals ruled against the University of California (UC) on CRISPR patents.
CRISPR pioneer Jennifer Doudna has set up shop in San Francisco’s Gladstone Institutes. Doudna, a UC Berkley professor credited with the co-discovery of CRISPR-Cas9 genome editing technique, will focus on the development of new ways to implement the gene-editing technique for disease treatment.
Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let’s take a look.
Cambridge, Mass.-based Editas Medicine, one of the leading CRISPR gene editing companies, is losing its chief medical officer. Gerald Cox will step down from his role at the end of the year.
Shares of CRISPR Therapeutics (-8 percent), Editas Medicines (-5 percent) and Intellia Therapeutics (-6.7 percent) are all plunging following the release of a report that claimed CRISPR-Cas9 gene editing may cause some dangerous side effects.
JOBS
IN THE PRESS